Search

Search Constraints

You searched for: Author/Creator Robinson, Angus

Search Results

1. Ten-year supra-network experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. (October 2019)

2. Long‐term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. (27th December 2020)

3. A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE. Issue 5 (8th November 2021)

4. Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Issue 4 (April 2022)

5. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Issue 10323 (29th January 2022)

6. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). Issue 3 (20th January 2021)

7. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Issue 1 (January 2020)

8. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Issue 10274 (13th February 2021)

9. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance. Issue 9 (September 2016)

10. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Issue 4 (April 2023)